Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | BRAF V600E CD274 over exp |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
BRAF V600E CD274 over exp | lung adenocarcinoma | predicted - sensitive | Dabrafenib + Trametinib | Case Reports/Case Series | Actionable | In a clinical case study, second-line treatment with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in a clinical response lasting at least 5 years in a patient with lung adenocarcinoma harboring BRAF V600E and high CD274 (PD-L1) expression (TPS=100%) who did not respond to first-line Keytruda (pembrolizumab) (PMID: 38429896). | 38429896 |